Previous trial results showed signficant improvements in radiographic PFS and OS from adding apalutamide to ADT. The FDA recently approved the drug for metastatic castration-sensitive prostate cancer.
Medscape Medical News
Original Article: Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy